Skip to content
OpenCapital
Get started

Collegium Pharmaceutical, Inc. COLL Cash & Equivalents

Cash & Equivalents at other companies

Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc. INDV
$175M-53.0%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$755.86M+30.2%
Avanos Medical logo
Avanos MedicalAVNS
$65.6M-32.4%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$144.31M-49.1%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$186.32M+60.8%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$288.1M+160%

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.15B+20.4%
Enterprise value$869.67M+2.5%
P/E15.4×-6.4×
P/S1.5×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0×0.0×
Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s cash & equivalents?
Collegium Pharmaceutical, Inc. (COLL) reported cash & equivalents of $289.56M in Q1 2026.
How has Collegium Pharmaceutical, Inc.'s cash & equivalents changed year-over-year?
Collegium Pharmaceutical, Inc.'s cash & equivalents increased by 147.3% year-over-year, from $117.09M to $289.56M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Collegium Pharmaceutical, Inc.'s cash & equivalents has grown at a 7.7% compound annual growth rate (CAGR), from $174.12M to $252.16M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.